AF
DSGN icon

Amalgamated Financial’s Design Therapeutics DSGN Stock Holding History

Amalgamated Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$63K Buy
+3,871
New +$59.3K ﹤0.01% 2310

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amalgamated Financial's DSGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Design Therapeutics (DSGN) in Q1 2022: 3,871 shares worth $63K. The stake represents ﹤0.01% of the portfolio and ranks #2310 among its holdings.

63 funds tracked by Wall St. Rank hold DSGN as of Q1 2022.

  • Amalgamated Financial held 3,871 shares of Design Therapeutics worth $63K as of Q1 2022.
  • Design Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Design Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2310 holding.
  • 63 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.